HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Vanesa Gregorc Selected Research

human CNGRC fusion protein tumor necrosis factor-alpha

10/2018NGR-hTNF and Doxorubicin as Second-Line Treatment of Patients with Small Cell Lung Cancer.
1/2018NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial.
12/2013Peptide-mediated targeting of cytokines to tumor vasculature: the NGR-hTNF example.
4/2011Phase I study of NGR-hTNF, a selective vascular targeting agent, in combination with cisplatin in refractory solid tumors.
5/2010Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma.
1/2010Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Vanesa Gregorc Research Topics

Disease

43Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2022 - 01/2003
26Neoplasms (Cancer)
01/2022 - 01/2003
9Lung Neoplasms (Lung Cancer)
01/2022 - 07/2003
5Disease Progression
11/2021 - 07/2003
3Chills
01/2018 - 01/2010
2Heart Failure
01/2022 - 08/2007
2Brain Neoplasms (Brain Tumor)
09/2021 - 01/2018
2Neoplasm Metastasis (Metastasis)
09/2021 - 02/2019
2Melanoma (Melanoma, Malignant)
09/2021 - 01/2020
2Small Cell Lung Carcinoma (Small Cell Lung Cancer)
12/2018 - 10/2018
2Malignant Mesothelioma
01/2018 - 05/2010
2Neutropenia
01/2018 - 06/2014
1Dilated Cardiomyopathy (Cardiomyopathy, Congestive)
01/2022
1Breast Neoplasms (Breast Cancer)
11/2021
1Chronic Obstructive Pulmonary Disease (COPD)
01/2020
1Hypertension (High Blood Pressure)
01/2020
1COVID-19
01/2020
1Hypoglycemia (Reactive Hypoglycemia)
09/2019
1Polyneuropathies (Polyneuropathy)
03/2019
1Nervous System Diseases (Neurological Disorders)
03/2019
1Bell Palsy (Bell's Palsy)
03/2019
1Myasthenia Gravis
03/2019
1Brain Diseases (Brain Disorder)
03/2019
1Pulmonary Aspergillosis
02/2019
1Invasive Pulmonary Aspergillosis
02/2019
1Superinfection
02/2019
1Colitis
02/2019
1Opportunistic Infections (Opportunistic Infection)
02/2019
1Aspergillosis
02/2019
1Hepatitis
02/2019
1Pneumonia (Pneumonitis)
02/2019
1Pancreatitis
02/2019
1Adenocarcinoma of Lung
02/2019
1Edema (Dropsy)
02/2019
1Pseudomonas Infections
02/2019
1Pain (Aches)
01/2018
1Vascular Tissue Neoplasms
12/2013
1Mesothelioma
09/2012

Drug/Important Bio-Agent (IBA)

17ErbB Receptors (EGF Receptor)IBA
01/2022 - 07/2003
8Tyrosine Kinase InhibitorsIBA
01/2022 - 08/2004
7Gefitinib (Iressa)FDA Link
08/2014 - 07/2003
6Proteins (Proteins, Gene)FDA Link
04/2021 - 12/2003
6human CNGRC fusion protein tumor necrosis factor-alphaIBA
10/2018 - 01/2010
6Cisplatin (Platino)FDA LinkGeneric
09/2012 - 01/2003
5PlatinumIBA
11/2021 - 07/2003
5Biomarkers (Surrogate Marker)IBA
01/2021 - 09/2004
5Erlotinib Hydrochloride (CP 358,774)FDA Link
01/2018 - 05/2010
4Immune Checkpoint InhibitorsIBA
09/2020 - 01/2017
4Peptides (Polypeptides)IBA
12/2013 - 01/2010
3LigandsIBA
11/2021 - 01/2010
3Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
01/2020 - 05/2005
3CD13 Antigens (Alanine Aminopeptidase)IBA
04/2011 - 01/2010
3Pharmaceutical PreparationsIBA
05/2010 - 12/2006
3DNA (Deoxyribonucleic Acid)IBA
05/2008 - 05/2005
2Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2022 - 10/2004
2Biological ProductsIBA
04/2021 - 09/2019
2osimertinibIBA
11/2019 - 04/2018
2NivolumabIBA
03/2019 - 02/2019
2pembrolizumabIBA
03/2019 - 02/2019
2Circulating Tumor DNAIBA
01/2019 - 11/2018
2Docetaxel (Taxotere)FDA Link
01/2019 - 01/2017
2Epidermal Growth Factor (EGF)IBA
11/2018 - 05/2005
2Anaplastic Lymphoma KinaseIBA
02/2018 - 01/2018
2Pemetrexed (MTA)FDA Link
01/2018 - 09/2012
2asparagine-glycine-arginineIBA
04/2011 - 05/2010
2Protein Isoforms (Isoforms)IBA
05/2010 - 01/2010
2Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
05/2010 - 08/2007
1AutoantibodiesIBA
01/2022
1tocilizumab (atlizumab)FDA Link
11/2021
1AntibodiesIBA
01/2021
1DeoxyuridineIBA
10/2020
1TAS-114IBA
10/2020
1ORALIT (ORS)IBA
01/2020
1Glucose (Dextrose)FDA LinkGeneric
09/2019
1SuspensionsIBA
03/2019
1Carbapenems (Carbapenem Antibiotics)IBA
02/2019
1Adrenal Cortex Hormones (Corticosteroids)IBA
02/2019
1Tumor Necrosis FactorsIBA
02/2019
1nintedanibIBA
01/2019
1Temozolomide (Temodar)FDA LinkGeneric
12/2018
1veliparibIBA
12/2018
1RNA (Ribonucleic Acid)IBA
11/2018
1Doxorubicin (Adriamycin)FDA LinkGeneric
10/2018
1CrizotinibIBA
02/2018
1ceritinibIBA
02/2018
1B7-H1 AntigenIBA
01/2018
1Histone Deacetylase InhibitorsIBA
08/2017
1abexinostatIBA
08/2017
1Angiogenesis InhibitorsIBA
01/2017
1AfatinibIBA
08/2014
1CytokinesIBA
12/2013

Therapy/Procedure

16Drug Therapy (Chemotherapy)
01/2022 - 01/2003
15Therapeutics
11/2021 - 05/2004
7Immunotherapy
09/2021 - 01/2017
3Radiotherapy
01/2018 - 01/2007
2Extracorporeal Membrane Oxygenation
01/2022 - 09/2019
2Aftercare (After-Treatment)
12/2012 - 06/2007
1Precision Medicine
01/2021
1Critical Care (Surgical Intensive Care)
01/2020
1Lasers (Laser)
01/2012